S. Kathirvel et al., Effect of prophylactic ondansetron on postoperative nausea and vomiting after elective craniotomy, J NEUROS AN, 13(3), 2001, pp. 207-212
This prospective, randomized, placebo-controlled, double-blind study was de
signed to evaluate the efficacy of ondansetron, a 5-HF3, antagonist, in pre
venting postoperative nausea and vomiting (PONV) after elective craniotomy
in adult patients. The authors also tried to discover certain predictors fo
r postcraniotomy nausea and vomiting. We studied 170 ASA physical status I
and II patients, aged 15 to 70 years, undergoing elective craniotomy for re
secting various intracranial tumors and vascular lesions. A standardized an
esthesia technique and postoperative analgesia were used for all patients.
Patients were divided into two groups and received either saline placebo (G
roup 1) or ondansetron 4 mg (Group 2) intravenously at the time of dural cl
osure. Patients were extubated at the end of surgery and episodes of nausea
and vomiting were noted for 24 hours postoperatively in the neurosurgical
intensive care unit. Demographic data, duration of surgery, and anesthesia
and analgesic requirements were comparable in both groups. Overall, a 24-ho
ur incidence of postoperative emesis was significantly reduced in patients
who received ondansetron compared with those who received a saline placebo
(39% in Group 1 and 11% in Group 2, P =.001). There was a significant reduc
tion in the frequency of emetic episodes and rescue antiemetic requirement
in patients treated with ondansetron; however, ondansetron did not signific
antly reduce the incidence of nausea alone (14% in Group 2 vs 5% in Group 1
, P =.065). Prophylactic ondansetron had a favorable influence on PONV outc
ome measures such as patient satisfaction and number needed to prevent emes
is (3.5). Side effects were similar in both groups. We conclude that ondans
etron 4 mg given at the time of dural closure is safe and effective in prev
enting emetic episodes after elective craniotomy in adult patients.